PRICE CUT BY ELI LILLY
Major Price Cut by Eli Lilly: Humalog & Humulin Now More Affordable
Eli Lilly will cut the list price of its most commonly prescribed insulin, Humalog and Humulin, by 70% in the fourth quarter this year. This price cut by Eli Lilly aims to make insulin more affordable for millions of diabetes patients, addressing concerns over rising medication costs.
Insulin price cut by Eli Lilly, Novo Nordisk, and Sanofi marks a major reduction by top pharma giants in the USA, making diabetes treatment more affordable.
| NOVO NORDISK | SANOFI PHARMA | ELI LILLY PHARMA |
|---|---|---|
| 75% price cut for insulin products | 78% price cut for insulin products | Humalog and Humulin, by 70%. |
Media reports confirm a price cut by Eli Lilly, reducing the cost of its widely used insulin products, Humalog and Humulin, by 70% to improve affordability for patients.
The decision comes in response to the growing criticism by US lawmakers over the rising cost of insulin, which has made it difficult for many Americans to afford the life-saving medication there are more than 8 million American who use insulin to control their diabetes according to the American Diabetes Associations.
The company will also cut the list price of its non-branded insulin ,Lispro , to $ 25 a vial from May 1st ,the increased price led to a public outcry, with many calling for pharmaceutical companies to take action to make insulin more affordable.
Eli Lilly’s decision to cut the price of insulin by 70% is a significant step towards addressing this issue. The company has stated that the new prices will go into effect in the fourth quarter of this year, and will apply to the most commonly prescribed forms of insulin, Humalog and Humulin.
The move has been welcomed by patient advocacy groups and lawmakers, who have been pushing for lower insulin prices for years. However, some critics have noted that the price reduction may not be enough to make insulin truly affordable for all patients, especially those who are uninsured or underinsured.
Despite this, the decision by Eli Lilly to cut insulin prices by 70% is being seen as a positive step towards making this life-saving medication more accessible and affordable for millions of Americans who rely on it to manage their diabetes.
